Medtech Start-Ups: Protaryx Med., ivWatch, Resistell, MastOR, & more

Published on Aug 12, 2020

MedtechUnicorn_NewProfiles2_LinkedIN

LSI's Medtech Start-Up Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.  

Protaryx Medical raises $5.1M in recent Series A

The company is developing a novel device that optimizes transseptal access to the left atrium during structural heart and catheter ablation procedures. To-date, the company has raised $8.3M. Key strategics in the structural heart devices market include Abbott, Edwards Lifesciences, and Medtronic.

Start a Free Trial to Medtech Start-Up Tracker Today

ivWatch is currently seeking to raise $13M in equity

As of early July 2020, the company has raised $1.5M of the $13M. The company FDA cleared technology functions as a continuous intravenous monitoring system for the early detection of peripheral IV infiltration and extravasation events. To-date, the company has raised $23.1M. ivWatch’s SmartTouch sensor recently received FDA clearance.

Point-of-care antibiotic resistance test developer Resistell receives European Innovation Council grant

The company received a $2.8M grant from the European Innovation Council to help finance the final development stages of the company’s device and disposables. Resistell’s point-of-care test can detect bacterial resistance to antibiotics in minutes, rather than days. The company’s technology will compete in the larger POC testing market against market leaders such as biomerieux, Cepheid, and Roche.

MastOR is developing a surgical robotic system to assist with laparoscopies

The robotic platform is intended to be an affordable, modular, and ubiquitous system. The company is initially focused on developing the platform to assist with hernia repair and cholecystectomies. The surgical robotics market has accelerated in growth within the last decade. Many medtech companies, such as Globus Medical and Medtronic, have followed the successful trail blazed by Intuitive Surgical

Digital therapeutic developer Ampersand is using behavioral science to help patients manage chronic inflammatory diseases

The company recently raised an undisclosed amount from investors at Crista Galli Ventures and NCL Technology Ventures. Ampersand offers two digital therapeutic platforms for the management of arthritis and symptoms associated with Chron’s and Colitis. Other competitors in the digital therapeutics market include Pear Therapeutics, Proteus Health, and Livongo.

Norlase, developer of an affordable green laser photocoagulator, completes Series A round

With the recent round, the company has raised a total of $10.4M. The company’s LEAF system is FDA-cleared for the treatment of retinal disease and glaucoma. Key strategics in this market include Lumenis and Iridex, among others.

Cloud-based cardiac imaging software platform from inHEART will assist electrophysiologists with 3D mapping technology

inHeart recently raised $4.2M in a seed round. The company’s imaging technology generates a 3D map a patient’s heart from CT and MRI images. Major competitors in this market include Abbott, J&J subsidiary Biosense Webster, and Medtronic, among others.

Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Start-Up Tracker.

Topics: Medtech, Medtech Venture Capital, Strategics

Join us at the next LSI Emerging Medtech Summit

LSI's global events attract top innovators, active investors, and deal-making strategics.

GET INFO

Our Clients